Shashikant Apte

Director
Sahyadri Speciality Hospital, Pune, Maharashtra, India

Presentation(s):

• OC 40.5 - Crimson 1: A Phase 3 study to evaluate the efficacy and safety of subcutaneous marzeptocog alfa (activated) for on-demand treatment of bleed events in subjects with hemophilia A or B, with inhibitors

  Monday, July 11, 2022
  3:45 PM – 4:00 PM

• PB1163 - Real-World Unmet Needs of Patients with Haemophilia A/B with or without Inhibitors: Historical Haemophilia Characteristics from Patients Entering a Non-Interventional Study

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM